tbuckley/cabot-search huggingface dataset:
632P Health-related quality of life (HRQoL) at final analysis of the SPARTAN study of apalutamide (APA) vs placebo (PBO) in patients (pts) with non-metastatic castration-resistant prostate cancer (nmCRPC) receiving androgen deprivation therapy (ADT)
Authors: S. Oudard, B.A. Hadaschik, F. Saad, D. Cella, E. Basch, P.N. Mainwaring, J.N. Graff, S. Dibaj, S. Li, S.D. Brookman-May, P. De Porre, J.J. Trudeau, E.J. Small, M.R. Smith
Journal: Annals of Oncology (2020)
1712P Risk of SARS-CoV-2 infection and outcome after infection: Experience from the day-care unit at CHU Liège in Belgium
Authors: M. Lecocq, C.E. Onesti, H. Schroeder, A. Rorive, M. Goffin, E. Gonne, B. Sautois, A. Catot, O. Wera, L. Nicolaers, A. Collinge, J. Collignon, P. Freres, M. Polus, B. Duysinx, F. Vaillant, C. Gennigens, N. Marchal, A. Poncin, G. Jerusalem
Journal: Annals of Oncology (2020)
440P Phase III randomized trial comparing short-term infusion of oxaliplatin and capecitabine (Xelox30) with chronomodulated (Xelox30) in patients with advanced and/or metastatic colorectal cancer
Authors: M.Q. Nafea, S.H. Mahmoud, N.M. Gado, Z.M. Abdel Hafeez, K.K-E. El-Ghonemy
Journal: Annals of Oncology (2020)
56P Anti-PD1 antibody toripalimab, lenvatinib and gemox chemotherapy as first-line treatment of advanced and unresectable intrahepatic cholangiocarcinoma: A phase II clinical trial
Authors: J. Zhou, J. Fan, G. Shi, X. Huang, D. Wu, G. Yang, N. Ge, Y. Hou, H. Sun, X. Huang, Y. He, S. Qiu, X. Yang, Y. Xu, Q. Gao, C. Huang, J. Lu, Q. Sun, F. Liang
Journal: Annals of Oncology (2020)
1437P Can FDG-PET predict early disease relapse in patients receiving peri-operative FLOT for localised oesophago-gastric adenocarcinoma?
Authors: P. Seeva, N. Tinne, C. Baker, A. Davies, J. Gossage, M. Kelly, A. Qureshi, K. Owczarczyk, S. Ngan, A. Sita-Lumsden, R. Kwong, S. Chowdhury, N. Maisey
Journal: Annals of Oncology (2020)
1822P Impact of iron-deficiency management on quality of life in cancer patients: A prospective cohort study (CAMARA study)
Authors: C. Gluszak, M. De Vries-Brilland, V. Seegers, N. Panouilleres, C. Baroin, H. Kieffer, R. Delva, D. Cornuault-Foubert
Journal: Annals of Oncology (2020)
803TiP Pilot study of cabozantinib efficacy, safety and tolerability in metastatic renal carcinoma in aged fragile patients
Authors: M.A. Climent Duran, L. Basterretxea, R. Sanchez Escribano, E. Llabres, L. Heras Lopez, F. Zambrana, M.D. Torregrosa, R. Girones Sarrio, J.C. Villa Guzman, M.J. Juan Fita, N. Fernandez Nuñez
Journal: Annals of Oncology (2020)
372MO Melanoma leptomeningeal metastases: A European multicenter cohort
Authors: E. Le Rhun, J. Weller, K. Seystahl, J. Jongen, M.J. van den Bent, D. Brandsma, M. Preusser, R. Rudà, F. Wolpert, U. Herrlinger, L. Mortier, R. Dummer, M. Weller
Journal: Annals of Oncology (2020)
62P Prognostic significance of baseline neutrophil lymphocyte ratio (NLR), platelet lymphocyte ratio (PLR) and systemic immune-inflammation index (SII) in patients (pts) with biliary tract cancer (BTC)
Authors: N-U-A. Tariq, H. Raja, X. Wang, S. Mehta, A. Lamarca, R. Hubner, M.G. McNamara, J.W. Valle
Journal: Annals of Oncology (2020)
1696P Incidence of influenza-like illness (ILI) in cancer patients during COVID-19: The ONCOVID prospective observational study
Authors: F. Grossi, M. Cattaneo, E. Rijavec, M. Ghidini, C. Bareggi, B. Galassi, D. Gambini, E. Berti, A. Indini
Journal: Annals of Oncology (2020)
2011P The impact of pathological response (PR) on adjuvant chemotherapy (AC) decisions and patient outcomes in gastrointestinal cancers (GIC)
Authors: S. Bhalla, H. Zhu, J-Y. Lin, U. Özbek, E.J. Wilck, S. Chang, X. Chen, S. Ward, N. Harpaz, A. Polydorides, W. Miller, M.I. Fiel, I. Modica, W. Fan, N. Zeizafoun, C. Ang
Journal: Annals of Oncology (2020)
1293P IMpower150: Updated efficacy analysis in patients with EGFR mutations
Authors: M. Reck, T. Mok, M.A. Socinski, R.M. Jotte, D.W-T. Lim, F. Cappuzzo, F.J. Orlandi, D. Stroyakovskiy, N. Nogami, D. Rodriguez-Abreu, D. Moro-Sibilot, C.A. Thomas, F. Barlesi, G. Finley, G. Shankar, W. Yu, D. Merritt, M. Nishio
Journal: Annals of Oncology (2020)
1487P Prognostic impact of thyroid hormone status in resectable gastroesophageal cancer
Authors: H.C. Puhr, T.J. Reiter, P. Wolf, M.J. Mair, M. Paireder, R. Asari, S.F. Schoppmann, A.S. Berghoff, M. Preusser, A. Ilhan-Mutlu
Journal: Annals of Oncology (2020)
412P Six-year updated results of Japan Clinical Oncology Group study (JCOG0910): Randomized phase III study of adjuvant chemotherapy with S-1 versus capecitabine in patients with stage III colorectal cancer
Authors: T. Hamaguchi, Y. Shimada, J. Mizusawa, Y. Kanemitsu, A. Shiomi, K. Komori, M. Ohue, J. Watanabe, N. Takiguchi, Y. Nishizawa, Y. Takii, H. Ojima, T. Funakoshi, T. Kato, T. Kobatake, T. Yamaguchi, A. Takashima, H. Katayama, H. Fukuda
Journal: Annals of Oncology (2020)
1103P Long-term survival of real-world advanced melanoma patients treated with targeted therapy
Authors: R. Ismail, A. de Boer, M. van Dartel, D. Hilarius, M. van Zeijl, F. van den Eertwegh, M. Aarts, F. Van den Berkmortel, M. Boers-Sonderen, J.W.B. de Groot, J.B.A.G. Haanen, G.A.P. Hospers, E. Kapiteijn, D. Piersma, R. van Rijn, K.P.M. Suijkerbuijk, A.J. ten Tije, A.A.M. Van der Veldt, G. Vreugdenhil, M. Wouters
Journal: Annals of Oncology (2020)
Efficacy of Plinabulin vs Pegfilgrastim for Prevention of Chemotherapy-Induced Neutropenia in Adults With Non–Small Cell Lung Cancer
Authors: Douglas W. Blayney, Qingyuan Zhang, Jifeng Feng, Yanqiu Zhao, Igor Bondarenko, Ihor Vynnychenko, Nadezhda Kovalenko, Santosh Nair, Emad Ibrahim, Dmitriy Petrovich Udovista, Ramon Mohanlal, Stephan Ogenstad, Ene Ette, Lihua Du, Lan Huang, Yuan-kai Shi
Journal: JAMA Oncology (2020)

<h3>Importance</h3> Plinabulin is a novel, non–granulocyte colony-stimulating factor (GCSF) small molecule with both anticancer and neutropenia-prevention effects. <h3>Objective</h3> To assess the efficacy and safety of plinabulin compared with pegfilgrastim for the prevention of chemotherapy-induced neutropenia following docetaxel chemotherapy in patients with non–small lung cancer. <h3>Design, Setting, and Participants</h3> This was a randomized, open-label, phase 2 clinical trial of 4 treatment arms that was conducted in 19 cancer treatment centers in the United States, China, Russia, and Ukraine. Participants were adult patients with non–small cell lung cancer whose cancer had progressed after platinum-based chemotherapy. Data were collected from April 2017 through March 2018 and analyzed from August 2019 through February 2020. <h3>Interventions</h3> All patients received docetaxel 75 mg/m<sup>2</sup>on day 1 and were randomly assigned to 1 of 3 doses of plinabulin (5, 10, or 20 mg/m<sup>2</sup>) on day 1 or to pegfilgrastim 6 mg on day 2. Patients were treated every 21 days for 4 chemotherapy cycles. <h3>Main Outcomes and Measures</h3> The primary end point was the determination of the recommended phase 3 dose of plinabulin based on the days of severe neutropenia during chemotherapy cycle 1. Daily complete blood cell counts and absolute neutrophil counts were drawn during times of anticipated neutropenia during cycle 1. <h3>Results</h3> Of the 55 patients randomized and evaluated, the mean (SD) age was 61.3 (10.2) years, and 38 (69.1%) were men. With each escalation of the plinabulin dose, the incidence of any grade of neutropenia decreased. There were no significant differences in mean (SD) days of severe neutropenia among those treated with pegfilgrastim (0.15 [0.38] days) when dosed at day 2 vs plinabulin 20 mg/m<sup>2</sup>(0.36 [0.93] days;<i>P</i> = .76) when dosed at day 1, and no safety signals were detected. <h3>Conclusions and Relevance</h3> Single dose-per-cycle plinabulin has a similar neutropenia protection benefit as pegfilgrastim. Plinabulin 40 mg fixed dose, which is pharmacologically equivalent to 20 mg/m<sup>2</sup>, will be compared with pegfilgrastim 6 mg in the phase 3 portion of this trial. Noninferior days of severe neutropenia will be the primary end point, and bone pain reduction, thrombocytopenia reduction, and quality of life maintenance will be secondary end points. <h3>Trial Registration</h3> ClinicalTrials.gov Identifier:NCT03102606
766P Prognostic effect of systemic immune-inflammation index (SII) in 987 patients with advanced/metastatic urinary tract carcinoma (mUTC) treated with atezolizumab in the real-world global SAUL study
Authors: M. Mego, R.A. Huddart, J. Voortman, M. Ong, C. Gedye, H. Gurney, A.P. Fay, A. Bamias, B. Mellado Gonzalez, Y. Loriot, A.S. Merseburger, D. Castellano Gauna, S. de Ducla, J. Pavlova, S. Fear, C.N. Sternberg
Journal: Annals of Oncology (2020)
1068P Rescue chemotherapy (CT) after immune-oncology (IO) drugs in patients (pts) with refractory solid tumours: A propensity score (PS) matched cohort study
Authors: V. Galvão, F.J. Ros Montañá, I. Matos, C. Viaplana, G. Villacampa Javierre, I. Braña, A.B. Azaro Pedrazzoli, M. Vieito Villar, O. Saavedra Santa Gadea, G. Alonso Casal, A. Hernando-Calvo, J. Carles, T. Macarulla Mercade, E. Munoz Couselo, E. Elez, E. Felip, J. Tabernero, R. Dienstmann, M. Oliveira, E. Garralda
Journal: Annals of Oncology (2020)
3次元コラーゲン I は,膵癌において, MT1-MMP介在HMGA2発現を介して,ゲムシタビン抵抗性を促進する
Authors: Dangi-Garimella Surabhi, B Krantz Seth, R Barron Morgan, A Shields Mario, J Heiferman Michael, J Grippo Paul, J Bentrem David, G Munshi Hidayatullah
Journal: Cancer Research (2011)
Genomic predictors of central nervous system relapse in primary testicular diffuse large B-cell lymphoma
Authors: David D. W. Twa, Derrick G. Lee, King L. Tan, Graham W. Slack, Susana Ben-Neriah, Diego Villa, Joseph M. Connors, Laurie H. Sehn, Anja Mottok, Randy D. Gascoyne, David W. Scott, Christian Steidl, Kerry J. Savage
Journal: Blood (2020)
Age-associated mitochondrial DNA mutations cause metabolic remodeling that contributes to accelerated intestinal tumorigenesis
Authors: Anna L. M. Smith, Julia C. Whitehall, Carla Bradshaw, David Gay, Fiona Robertson, Alasdair P. Blain, Gavin Hudson, Angela Pyle, David Houghton, Matthew Hunt, James N. Sampson, Craig Stamp, Grace Mallett, Shoba Amarnath, Jack Leslie, Fiona Oakley, Laura Wilson, Angela Baker, Oliver M. Russell, Riem Johnson, Claire A. Richardson, Bhavana Gupta, Iain McCallum, Stuart A. C. McDonald, Seamus Kelly, John C. Mathers, Rakesh Heer, Robert W. Taylor, Neil D. Perkins, Doug M. Turnbull, Owen J. Sansom, Laura C. Greaves
Journal: Nature Cancer (2020)
630P Apalutamide for non-metastatic castration resistant prostate cancer (nmCRPC): A comparison of real-life experience from an international named patient program (NPP) vs the prior phase III clinical study
Authors: H.A. Payne, M. Bulbul, K. Hatzimouratidis, S. Feyerabend, M. Kase, A. Manduley, J. McCaffrey, G. Procopio, M. Saad, M. Santoni, I. Sayers, T.J. Schnöller, O. Shatkovskaya, L. Antoni, J. Diels, A. Lopez-Gitlitz, S. McCarthy, S.D. Mundle, G. Pissart, M. Bögemann
Journal: Annals of Oncology (2020)
1300P Intracranial efficacy of brigatinib (BRG) vs crizotinib (CRZ): Updated results from the ALTA-1L trial
Authors: S. Popat, H.R. Kim, M-J. Ahn, J.C-H. Yang, J-Y. Han, M.J. Hochmair, K.H. Lee, A. Delmonte, M.R. Garcia Campelo, D-W. Kim, F. Griesinger, E. Felip, R. Califano, A. Spira, S. Gettinger, M. Tiseo, Q. Ni, P. Zhang, D.R. Camidge
Journal: Annals of Oncology (2020)
728P Primary resistance (PrR) versus acquired resistance (AcR) to immune checkpoint inhibitors (ICI) in first-line metastatic renal cell carcinoma (mRCC)
Authors: A. Guida, C. Alves Costa Silva, E. Colomba-Blameble, R. Flippot, F. Salviat, S. Bracarda, B. Escudier, L. Albiges
Journal: Annals of Oncology (2020)
1061P TCR and HLA analysis of patients in a phase I/IIa trial of a therapeutic CMV vaccine against recurrent glioblastoma (GBM)
Authors: D.E. Anderson, A. Zilberberg, H. Philip, M. Gordon, A-C. Fluckiger, S. Efroni, F. Diaz-Mitoma
Journal: Annals of Oncology (2020)
1626MO Treatment expectations and preferences for quality versus quantity of life in patients with advanced soft tissue sarcomas starting palliative 1st line chemotherapy
Authors: E. Younger, R.L. Jones, D. Den Hollander, V. Soomers, I.M.E. Desar, R. Young, A. Oosten, H. Gelderblom, J.J. De Haan, N. Steeghs, O. Husson, W.T.A. Van Der Graaf
Journal: Annals of Oncology (2020)
Anti-granulocyte-macrophage colony-stimulating factor antibody otilimab in patients with hand osteoarthritis: a phase 2a randomised trial
Authors: Georg Schett, Chris Bainbridge, Mario Berkowitz, Katherine Davy, Sofia Fernandes, Eduard Griep, Stephen Harrison, Anubha Gupta, James Lloyd-Hughes, Alexandra Roberts, Mark Layton, Nonna Anna Nowak, Jatin Patel, Jürgen Rech, Julia E Smith, Sarah Watts, Paul P Tak
Journal: The Lancet Rheumatology (2020)
In Vivo-assembled phthalocyanine/albumin supramolecular complexes combined with a hypoxia-activated prodrug for enhanced photodynamic immunotherapy of cancer
Authors: Xingshu Li, Yun-Hui Jeon, Nahyun Kwon, Jun-Gyu Park, Tian Guo, Hang-Rae Kim, Jian-Dong Huang, Dong-Sup Lee, Juyoung Yoon
Journal: Biomaterials (2020)
530MO Clinical benefit in biomarker-positive patients (pts) with locally advanced or metastatic solid tumours treated with the PARP1/2 inhibitor pamiparib in combination with low-dose (LD) temozolomide (TMZ)
Authors: A. Stradella, M. Johnson, S. Goel, S.R. Chandana, M.D. Galsky, E. Calvo, V. Moreno, H. Park, T. Arkenau, A. Cervantes, L. Fariñas-Madrid, L. Mileshkin, S. Fu, R. Plummer, J. Evans, L. Horvath, A. Prawira, K. Qu, R. Pelham, M.A. Barve
Journal: Annals of Oncology (2020)
LBA51 KEYNOTE-024 5-year OS update: First-line (1L) pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) in patients (pts) with metastatic NSCLC and PD-L1 tumour proportion score (TPS) ≥50%
Authors: J.R. Brahmer, D. Rodriguez-Abreu, A.G. Robinson, R. Hui, T. Csőszi, A. Fülöp, M. Gottfried, N. Peled, A. Tafreshi, S. Cuffe, M. O'Brien, S. Rao, K. Hotta, T.A. Leal, J.W. Riess, E. Jensen, B. Zhao, M.C. Pietanza, M. Reck
Journal: Annals of Oncology (2020)
Why Adolescent Medicine?
Authors: Maria Trent
Journal: JAMA Pediatrics (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
333P Ribociclib (RIB) + letrozole (LET) in subgroups of special clinical interest with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC): Subgroup analysis from the CompLEEment-1 trial
Authors: P.H. Cottu, A. Ring, P. Marchetti, F. Cardoso, J. Salvador, P. Neven, K. Papazisis, M. Campone, T. Bachelot, L. Menon-Singh, J. Wu, K. Zhou, M. De Laurentiis
Journal: Annals of Oncology (2020)
Chemical Characterization of a Legacy Aqueous Film-Forming Foam Sample and Developmental Toxicity in Zebrafish ( <i>Danio rerio</i> )
Authors: Kate M. Annunziato, Jeffery Doherty, Jonghwa Lee, John M. Clark, Wenle Liang, Christopher W. Clark, Malina Nguyen, Monika A. Roy, Alicia R. Timme-Laragy
Journal: Environmental Health Perspectives (2020)

Background: Drinking water contamination related to the use of aqueous film-forming foam (AFFF) has been documented at hundreds of military bases, airports, and firefighter training facilities. AFFF has historically contained high levels of long-chain per- and polyfluoroalkyl substances (PFAS), which pose serious health concerns. However, the composition and toxicity of legacy AFFF mixtures are unknown, presenting great uncertainties in risk assessment and affected communities. Objectives: This study aimed to determine the fluorinated and nonfluorinated chemical composition of a legacy AFFF sample and its toxicity in zebrafish embryos. Methods: A sample of legacy AFFF (3% application formulation, manufactured before 2001) was provided by the Massachusetts Department of Environmental Protection. High resolution mass spectrometry (HRMS) was used to identify PFAS and nonfluorinated compounds, and a commercial laboratory measured 24 PFAS by a modified U.S. EPA Method 537.1. AFFF toxicity was assessed in zebrafish embryos in comparison with four major constituents: perfluorooctanesulfonic acid (PFOS); perfluorohexanesulfonic acid (PFHxS); sodium dodecyl sulfate (SDS); and sodium tetradecyl sulfate (TDS). End points included LC50 values, and sublethal effects on growth, yolk utilization, and pancreas and liver development. Results: We identified more than 100 PFAS. Of the PFAS detected, PFOS was measured at the highest concentration (9,410mg/L) followed by PFHxS (1,500mg/L). Fourteen nonfluorinated compounds were identified with dodecyl sulfate and tetradecyl sulfate the most abundant at 547.8 and 496.4mg/L, respectively. An LC50 of 7.41×10−4% AFFF was calculated, representing a dilution of the 3% formulation. TDS was the most toxic of the constituents tested but could not predict the AFFF phenotype in larval zebrafish. PFOS exposure recapitulated the reduction in length but could not predict effects on development of the liver, which was the tissue most sensitive to AFFF. Discussion: To our knowledge, this research is the first characterization of the chemical composition and toxicity of legacy AFFF, which has important implications for regulatory toxicology. https://doi.org/10.1289/EHP6470
1386P Anlotinib combined with whole brain radiation therapy (WBRT) for advanced non-small cell lung cancer with multiple brain metastases: An open-label, single-arm phase II trial
Authors: X. Zhu, H. Tao, C. Kong, X. Song, N. Zhang, C. Chen, N. Jiang, L. Zhao, P. Yan, X. He
Journal: Annals of Oncology (2020)
1739P Clinical features and prognostic factors on admission of a prospective cohort of COVID-19 positive cancer patients in a third-level hospital in Madrid, Spain
Authors: J. Fuentes Antras, A. Manzano, G. Marquina Ospina, M. PAZ, J. Benitez, J. Tejerina-Peces, C. Aguado, P. Pérez-Segura
Journal: Annals of Oncology (2020)
1978MO Tumour-infiltrating macrophages, PD-L1 and tumour/stroma ratio as independent prognostic factors in a well-defined European cohort of patients with oral squamous cell carcinoma
Authors: M. Dom, A. Heimann, D. Chan, L. Craciun, M. Hein, N. de Saint Aubain, P. Demetter
Journal: Annals of Oncology (2020)
1309P ARC-4: Efficacy and safety of AB928 plus carboplatin, pemetrexed and a PD-1 antibody in participants with metastatic non-small cell lung cancer (mNSCLC)
Authors: A. Spira, P. Conkling, A. Chaudhry, D.E. Colburn, H. Gilbert, M. Scharville, O. Gardner, K. Krishnan, M. Paoloni, M. Johnson
Journal: Annals of Oncology (2020)
806O Radical hysterectomy in cervical cancer patients with intraoperatively detected positive lymph node: ABRAX multicentric retrospective cohort study (ENGOT-Cx3/CEEGOG CX2)
Authors: D. Cibula, L. Dostalek, P. Hillemanns, G. Scambia, J. Persson, F. Raspagliesi, Z. Novak, A. Jaeger, M.E. Capilna, V. Weinberger, J. Klat, R.L. Schmidt, A. Lopez, G. Scibilia, R. Pareja, A. Kucukmetin, L. Kreitner, A. El-Balat, S. Laufhutte, I. Runnenbaum
Journal: Annals of Oncology (2020)
349TiP EPIK-B3: A phase III, randomised, double-blind (DB), placebo (PBO)-controlled study of alpelisib (ALP) + nab-paclitaxel (nab-PTX) in advanced triple-negative breast cancer (TNBC) with either PIK3CA mutation or phosphatase and tensin homolog (PTEN) loss without PIK3CA mutation
Authors: P. Sharma, A. Farooki, P.A. Fasching, S. Loi, K. Peterson, A. Prat, D. Tripathy, B. Xu, D.A. Yardley, D. Mills, G. Klauss, C. Wong, F. André
Journal: Annals of Oncology (2020)
913MO Second primary cancer after intensity-modulated radiotherapy for nasopharyngeal carcinoma in Hong Kong (2001-2010): A territory-wide study by HKNPCSG
Authors: J. Chow, A. Tam, K.M. Cheung, V.H.F. Lee, C.L. Chiang, M. Tong, E. Wong, A. Cheung, S. Chan, J. Lai, R. Ngan, W.T. Ng, A. Lee, K.H. Au
Journal: Annals of Oncology (2020)
597TiP A phase Ib study on a TRPV6-inhibitor, SORC13 in patients with advanced solid tumours
Authors: S. Fu, D. Hong, D. Fogelman, F. Shaikh, D. Dupont-Roettger, S. Bisdas, E.E. Ileana Dumbrava, S. Piha-Paul, L. Liu, D. Dugourd, Y. Yamamura
Journal: Annals of Oncology (2020)
LBA55 WJOG @Be study: A phase II study of atezolizumab (atez) with bevacizumab (bev) for non-squamous (sq) non-small cell lung cancer (NSCLC) with high PD-L1 expression
Authors: T. Seto, K. Nosaki, M. Shimokawa, R. Toyozawa, S. Sugawara, H. Hayashi, H. Murakami, T. Kato, S. Niho, H. Saka, M. Oki, H. Yoshioka, I. Okamoto, H. Daga, K. Azuma, H. Tanaka, K. Nishino, M. Satouchi, N. Yamamoto, K. Nakagawa
Journal: Annals of Oncology (2020)
“Double-surgical-mask-with-slit” method: reducing exposure to aerosol generation at upper gastrointestinal endoscopy during the COVID-19 pandemic
Authors: Nikolaos Lazaridis, Alexandros Skamnelos, Alberto Murino, Rocio Chacchi Cahuin, Nikolaos Koukias, Edward J. Despott
Journal: Endoscopy (2020)

See also: ESGE and ESGENA Position Statement on gastrointestinal endoscopy and the COVID-19 pandemicEndoscopy 2020; 52(06): 483-490DOI: 10.1055/a-1155-6229 See also: Double-surgical-mask-with-slit and COVID-19 preventionEndoscopy 2021; 53(01): 96-96DOI: 10.1055/a-1293-8107
Pharmacogenomics in Pediatric Oncology: Mitigating Adverse Drug Reactions While Preserving Efficacy
Authors: Abdelbaset A. Elzagallaai, Bruce C. Carleton, Michael J. Rieder
Journal: The Annual Review of Pharmacology and Toxicology (2020)

Cancer is the leading cause of death in American children older than 1 year of age. Major developments in drugs such as thiopurines and optimization in clinical trial protocols for treating cancer in children have led to a remarkable improvement in survival, from approximately 30% in the 1960s to more than 80% today. Short-term and long-term adverse effects of chemotherapy still affect most survivors of childhood cancer. Pharmacogenetics plays a major role in predicting the safety of cancer chemotherapy and, in the future, its effectiveness. Treatment failure in childhood cancer—due to either serious adverse effects that limit therapy or the failure of conventional dosing to induce remission—warrants development of new strategies for treatment. Here, we summarize the current knowledge of the pharmacogenomics of cancer drug treatment in children and of statistically and clinically relevant drug–gene associations and the mechanistic understandings that underscore their therapeutic value in the treatment of childhood cancer.
196P Neoadjuvant and adjuvant chemotherapy (NACT/ACT) treatment (tx) patterns in a real-world cohort of US pts with early triple-negative breast cancer (eTNBC)
Authors: L.A. Emens, C. Craggs, M. Debiasi, C. Flores-Avile, D. Incerti, M.K. Downer, P. Dhillon, E. Mittendorf
Journal: Annals of Oncology (2020)
1952P Comprehensive profiling of MDM2 amplified gastrointestinal (GI) cancers
Authors: F. Battaglin, J. Xiu, Y. Baca, A.F. Shields, R.M. Goldberg, A. Puccini, R. Tokunaga, H. Arai, J. Wang, N. Kawanishi, A. Seeber, I. Astaturov, A.C. Lockhart, W. Zhang, J.L. Marshall, W.M. Korn, H.J. Lenz
Journal: Annals of Oncology (2020)